SCHEMBL3490967

SCHEMBL3490967

Cc1cccc(CNS(=O)(=O)c2c(N)cc(Cl)cc2Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.49
TP53 P04637 3/20 0.45
GPR17 Q13304 1/20 0.45
POLB P06746 2/20 0.42
NR3C1 P04150 4/20 0.42
NR3C2 P08235 4/20 0.42
CYP3A4 P08684 3/20 0.41
PGR P06401 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CNR1 P21554 1/20 0.41
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
GUSB P08236 1/20 0.40
NAMPT P43490 1/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490966 0.88 TP53 (0.57) CYP19A1TP53GPR17NR3C1NR3C2
SCHEMBL9220640 0.87 NR3C1 (0.42) CYP19A1TP53POLBNR3C1NR3C2
SCHEMBL3490432 0.86 CYP19A1 (0.48) CYP19A1TP53NR3C1NR3C2CYP3A4
SCHEMBL8988729 0.86 CYP19A1 (0.51) CYP19A1TP53NR3C1NR3C2CYP3A4
SCHEMBL3488631 0.86 KMT2A (0.52) CYP19A1NR3C1NR3C2CYP3A4PGR
SCHEMBL3491178 0.85 LMNA (0.52) CYP19A1TP53POLBNR3C1NR3C2
SCHEMBL3489981 0.85 CYP19A1 (0.47) CYP19A1TP53POLBNR3C1NR3C2
SCHEMBL3490289 0.85 CYP19A1 (0.47) CYP19A1TP53NR3C1NR3C2CYP3A4
SCHEMBL9220257 0.85 ALDH1A1 (0.42) TP53NR3C1NR3C2CYP3A4PGR
SCHEMBL9220811 0.84 CYP19A1 (0.45) CYP19A1TP53POLBCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D CYP19A1 1375/4885TP53 4577/4885GPR17 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.